| Document Date: 2009-11-06 09:22:29
Open Document File Size: 183,51 KBShare Result on Facebook
City Lexington / / Company Flagship Ventures / TARIS Biomedical Inc. / Flybridge Capital Partners / Millennium Pharmaceuticals / Polaris Venture Partners / Coley Pharmaceuticals / Clinical Development / / Country United States / / Event Employment Change / / Facility University of Virginia / Medical College of Virginia / Massachusetts Institute of Technology / / IndustryTerm venture capital / drug-device convergence technology / data management / platform technology / pharmaceutical / biopharmaceutical industry / local minimally-invasive drug-device convergence products / / MedicalCondition bladder diseases / overactive bladder / disease / bladder disease / bladder cancer / Interstitial Cystitis / Allergy / chronic pelvic pain syndrome / pain / diseases / bladder syndrome / Infectious Diseases / Painful Bladder Syndrome / urinary tract infections / chronic hepatitis C / / Organization University of Virginia / Medical College of Virginia / Massachusetts Institute of Technology / / Person Robert Langer / APPOINTS JULIE LEKSTROM HIMES / Michael Cima / Julie Lekstrom Himes / Christine Bunt / / Position co-founder and COO / Chief Medical Officer / Vice President / Medical Director / / Product lidocaine / / ProvinceOrState Virginia / Maryland / Massachusetts / / Technology drug-delivery / platform technology / drug-device convergence technology / Human Genome / / URL www.tarisbiomedical.com / /
SocialTag |
TARIS APPOINTS JULIE LEKSTROM HIMES, MD, TO CMO POST Lexington, MA – November 6, 2009 – TARIS Biomedical, a specialty pharmaceutical company pioneering the field of drug-device convergence for targeted therapies, ann